Exploring drug action on Mycobacterium tuberculosis using affymetrix oligonucleotide genechips

Area of Science:

• Genomics and Bioinformatics
• Microbiology and Infectious Diseases
• Pharmacogenomics

Background:

• DNA microarrays are crucial for Mycobacterium tuberculosis research, but data correlation issues raise credibility concerns.
• The Affymetrix oligonucleotide array platform offers enhanced reliability for gene expression analysis.
• Previous studies have not utilized the Affymetrix system for M. tuberculosis pharmacogenomic research.

Purpose of the Study:

• To evaluate the Affymetrix array system's efficacy in monitoring drug-induced gene expression in M. tuberculosis.
• To compare findings with existing pharmacogenomic studies and perform cross-platform analysis.
• To assess the reliability of the Affymetrix system for anti-TB drug research and development.

Main Methods:

• Genome-wide gene expression profiling of M. tuberculosis treated with isoniazid (INH) and ethionamide using the Affymetrix array system.
• Bioinformatic analysis to identify up-regulated and down-regulated genes based on RNA hybridization and gene probe data.
• Cross-platform comparison and analysis of probe-set dependency for gene expression determination.

Main Results:

• The Affymetrix system successfully identified previously reported drug-induced genes and uncovered novel targets.
• Rv2524c (fas) was found to be induced by both INH and ethionamide, challenging prior observations.
• Up-regulated gene expression patterns correlate with drug mechanisms, while down-regulated patterns appear non-specific.

Conclusions:

• The Affymetrix array system is a reliable tool for M. tuberculosis pharmacogenomic studies.
• This platform enhances the identification of drug-induced genes, aiding anti-TB drug discovery.
• Careful probe-set selection is crucial for accurate gene expression analysis using microarrays.